A problem-oriented approach to liver disease in oncology patients

McDonald, G. B.; Frieze, D.
July 2008
Gut;Jul2008, Vol. 57 Issue 7, p987
Academic Journal
The article offers practical considerations of how to prevent, diagnose and treat hepatobiliary problems that arise in the midst of anti-cancer therapy in oncology patients. The disciplines of oncology, clinical pharmacology and hepatology have seen rapid growth in their respective literatures that deal with new anti-tumour agents. These agents include, pharmacokinetics, pharmacodynamics and pharmacogenomics of cancer therapies.


Related Articles

  • Q: What's adjuvant therapy?  // Mayo Clinic Guide to Women's Cancers;2005, p175 

    This article answers a question about adjuvant therapy. Adjuvant therapy is another name for additional treatment. Adjuvant therapy is given to a person who has no visible evidence of any leftover cancer after the first treatment--usually surgery--has been completed and who may be cured of his...

  • Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. Shaked, Yuval; Bocci, Guido; Munoz, Raquel; Man, Shan; Ebos, John M.L.; Hicklin, Daniel J.; Bertolini, Francesco; D'Amato, Robert; Kerbe, Robert S. // Current Cancer Drug Targets;Oct2005, Vol. 5 Issue 7, p551 

    Perhaps the most significant recent advance in oncology therapeutics has been the approval of various "molecularly targeted" anti-cancer drugs. Currently, there are a large number of similar drugs in early or late stage development, including antiangiogenic agents. Clinical development of such...

  • Receptor-Targeted Cancer Therapy. Richter, Mark; Hongtao Zhang // DNA & Cell Biology;May2005, Vol. 24 Issue 5, p271 

    Insight into the molecular mechanisms of malignant transformation is changing the way cancer is being treated. Conventional treatment strategies target the DNA of all dividing cells, resulting in a significantly increased risk of collateral toxicity. In addition, the accumulation of multiple...

  • Novel Clinical Trial Designs for Innovative Therapies. Schellens, J. H. M.; Beijnen, J. H. // Clinical Pharmacology & Therapeutics;Feb2009, Vol. 85 Issue 2, p212 

    There is a paradigm shift in oncology from the development of classical intravenously applied cytotoxic anticancer drugs to so-called targeted therapies with molecules that are often administered orally on a chronic daily basis. The dose-limiting toxicities of targeted therapies are frequently...

  • Update for Cancer Therapy with β-Lapachone. Pardee, Arthur B.; Li, Chiang J. // Medicinal Chemistry Reviews - Online;Apr2004, Vol. 1 Issue 2, p199 

    This article is an update of our recent review on β-lapachone [1]. Since then two dozen references on βlapachone that have direct relevance to cancer appeared. These are summarized here. Nearly 300 references on βlapachone are currently listed by PubMed.

  • From the editors.  // Nature Reviews Cancer;Nov2007, Vol. 7 Issue 11, p809 

    The author reflects on the challenges facing personalized cancer therapy. The more that is learned about the genetic, epigenetic and pre- and post-translational changes that occur in tumor cells, the more personalized therapy for cancer patients seems possible. However, the cost to third-party...

  • Current issues in the management of hepatocellular carcinoma. Daniele, B. // Annals of Oncology;Apr2013, Vol. 24 Issue suppl_2, pii5 

    No abstract available.

  • Congenital Hepatic Fibrosis. Tewarson, Ivan P.; Crowe, Peter; Verhagen, Arie D. // Clinical Pediatrics;Nov1964, Vol. 3 Issue 11, p679 

    Discusses the pathogenesis of congenital hepatic fibrosis. Cause of congenital hepatic fibrosis; Manifestations of the disease; Citation of case report about a ten-year-old white male with congenital hepatic fibrosis; Clinical diagnosis.

  • Clinical endpoints in trials of drugs for cancer: time for a rethink? Koopmans, P. P. // BMJ: British Medical Journal (International Edition);6/8/2002, Vol. 324 Issue 7350, p1389 

    Presents clinical endpoints in trials of drugs for cancer. Need for improvements in the market of drugs for lethal diseases, such as cancer; Suggestion that more attention should be given to clinical symptoms and quality of life and less to survival; How surrogate endpoints and biomarkers...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics